| answer text |
<p>The Department routinely corresponds with the Welsh Government and patient representatives
on making medicinal cannabis accessible to patients suffering from chronic pain. The
Government has allowed specialist doctors to prescribe cannabis-based products, where
clinically appropriate and in the best interests of patients. However, the National
Institute for Health and Care Excellence (NICE) recommends that cannabis-based products
for medicinal use are not offered to manage chronic pain in adults and that cannabidiol
(CBD) only be offered as part of a clinical trial.</p><p>NICE recognises the lack
of evidence to support the use of these medicines and recommends that further research
is carried out on the clinical and cost effectiveness of CBD as an additional treatment
for adults with fibromyalgia or for persistent treatment resistant neuropathic pain.
The National Institute for Health Research welcomes funding applications for research
into any aspect of human health, including chronic pain. As for all other medicines,
it is the responsibility of the manufacturers to generate the evidence required for
assessment by the Medicines and Healthcare products Regulatory Agency and NICE.</p>
|
|
